首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 再生醫學 > 幹細胞技術：全球市場展望（2011∼2021年）
產業/市場分類
生物科技 (1574)
分子標靶治療學 (131)
生技設備 (354)
生物材料 (53)
生物標記 (155)
以基因為基之藥物開發 (202)
再生醫學 (119)
抗體和免疫 (189)
個人化醫學 (51)
基因治療學和RNAi (102)
市場調查報告書

幹細胞技術：全球市場展望（2011∼2021年）

Stem Cell Technologies: World Market Outlook 2011-2021

出版商 Visiongain
出版日期 2011年05月 商品編碼 203833
內容資訊 英文 137 Pages
價格
US $ 2331 PDF by E-mail (Single User License)
US $ 4663 PDF by E-mail (Departmental License)
US $ 7772 PDF by E-mail (Site License)
US $ 10882 PDF by E-mail (Global Site License)


幹細胞技術：全球市場展望（2011∼2021年） 是由出版商Visiongain在2011年05月所出版的。 這份英文市場調查報告書包含137 Pages 價格從美金2331起跳。

簡介

本報告書內容包括:幹細胞的治療應用、技術趨勢、產品、服務概要的彙整、2011∼2021年的各分類預測等的SWOT分析、專家的見解、內容綱要摘記如下:

第1章 實施摘要

第2章 幹細胞技術的介紹

  • 何謂幹細胞
  • 幹細胞的分類
  • 幹細胞的起源

第3章 全球的幹細胞市場：2011∼2021年

  • 幹細胞市場的定義
  • 幹細胞市場的成長：2011∼2021年
  • 幹細胞治療
    • 市場預測：2011∼2021年
    • 幹細胞和骨再生
    • 幹細胞和再生醫療
    • 幹細胞美容外科
    • 無限制的幹細胞治療
  • 骨髄移植
    • 移植片對宿主拒絕反映和宿主對移植反應
    • 骨髄移植和醫療保險
    • 民間骨髄移植預測：2011∼2021年
    • 末梢血幹細胞移植
    • 臍帶血幹細胞移植
  • 幹細胞服務
    • 病患模式
    • 毒性篩選
    • 幹細胞服務市場預測：2011∼2021年
  • 血液銀行
    • 民間・政府血液銀行
    • 臍帶血銀行的贊否
    • 民間臍帶血銀行市場預測：2011∼2021年

第4章 促進幹細胞市場的企業

  • 幹細胞治療開發的主要企業
  • 幹細胞服務所提供的企業
  • 民間臍袋血銀行

第5章 幹細胞技術市場所影響的問題：2011∼2021年

  • 幹細胞市場的SWOT圖表：2011∼2021年
  • 強勢
  • 弱點
  • 機會
  • 威脅

第6章 幹細胞技術的治療應用：2011∼2021年

  • 短期的適應
    • 癌
    • 免疫疾病
    • 眼病
    • 整形外科
    • 糖尿病
  • 心血管疾病
  • 中樞神經系統疾病
    • 肌萎縮側索硬化症
    • 多發性硬化症
    • 阿茲海默症
    • 腦性麻痺
    • 巴金森氏症
    • 脊髄損傷
  • 增殖臟器

第7章 幹細胞市場的各地區分析：2011∼2021年

  • 幹細胞研究的全球拓展
  • 美國
  • 日本
  • 歐洲
  • 中國
  • 印度

第8章 研究訪談

第9章 結論

圖表

目錄

Abstract

How will the stem cells market develop this decade? Our new report shows you that emerging industry and market' s revenue potential from 2011 to 2021.

This report covers stem cells in therapeutic applications: technologies, products and services. You will assess events, opportunities and activities shaping that industry. We aim to save you time and aid your decisions through our research, analysis and discussions.

Our new study shows you revenue prospects for stem cells at total world, submarket and product levels to 2021. What activities will expand that market from 2011 to 2021? Our work helps you to understand the stem cells industry and market.

When will significant numbers of stem cell therapies be launched? Which disease areas hold the greatest potential for stem cell therapies? We show you which markets will provide the best opportunities for research, product development and business from 2011 onwards.

What are the most crucial drivers and restraints in the development of stem cell therapies? How significant are other uses for stem cells, beyond therapy? Our report provides data and answers you need.

We help you to assess the stem cell industry and market' s strengths, weaknesses, trends and revenue opportunities to 2021. You will see where stem cell technologies are heading.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Industry and market analysis to help your work - so you won' t be left behind

Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review and analysis of companies, technologies and regulations, as well as opinions from our survey.

We include 66 tables and charts and a research interview (shown in the accompanying lists). In particular, we cover research and applications involving pluripotent and multipotent stem cells for human use.

Stem Cell Technologies: World Market Outlook 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

  • You will receive hard data for the stem cells industry and market - especially our revenue forecasts to 2021
  • You will discover revenue predictions for the overall market from 2011 to 2021
  • You will receive market forecasts for the main subsectors - stem cell therapies, stem cell services, cord blood banking and bone marrow transplants
  • You will discover revenue prospects to 2021 for the leading stem cell product
  • You will find out which disease areas are receiving the most attention from researchers and how soon treatments can be launched
  • You will receive analysis of the uses of stem cells and discussion of the commercial prospects for their use beyond therapy
  • You will review stem cell regulations, research and related activities in the US, Japan, Germany, France, Spain, the UK, Italy, China, India, Israel and South Korea
  • You will identify the leading companies in stem cell therapies, stem cell services and cord blood banking - we discuss the activities of over 40 companies there
  • You will investigate competition and opportunities influencing the industry and market
  • You will see what will stimulate and restrain the industry and market from 2011
  • You will analyse opportunities and challenges for established companies and those seeking to enter the stem cells market from 2011
  • You will review the technologies in development, assessing stem cell R&D potential
  • You will view opinion from our industry survey.

That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge for stem cell technologies.

Table of Contents

1. Executive Summary

  • 1.1 Overview of Findings
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods
    • 1.3.1 Speculative Aspects of Assessing the Stem Cell Field

2. Introduction to Stem Cell Technologies

  • 2.1 What Are Stem Cells?
  • 2.2 How Are Stem Cells Classified?
    • 2.2.1 Totipotency
    • 2.2.2 Pluripotency
    • 2.2.3 Multipotency
    • 2.2.4 Oligopotency
    • 2.2.5 Unipotency
  • 2.3 Where Do Stem Cells Come From?
    • 2.3.1 Embryonic Stem Cells
      • 2.3.1.1 Abortion Debates, IVF and Embryonic Stem Cells
      • 2.3.1.2 Harvesting Human Eggs
    • 2.3.2 Adult Stem Cells
    • 2.3.3 Umbilical Cord Blood Stem Cells

3. The Global Stem Cells Market 2011-2021

  • 3.1 Defining the Stem Cells Market
  • 3.2 Growth in the Stem Cells Market 2011-2021
  • 3.3 Stem Cell Therapies
    • 3.3.1 Stem Cell Therapies Market Forecast 2011-2021
    • 3.3.2 Stem Cells and Bone Regeneration
      • 3.3.2.1 Osteocel Plus (NuVasive)
      • 3.3.2.2 Osteocel Plus Sales Forecast 2011-2021
      • 3.3.2.3 Other Orthopaedic Stem Cell Products
    • 3.3.3 Stem Cells and Regenerative Medicine
    • 3.3.4 Stem Cell Cosmetics
    • 3.3.5 Unregulated Stem Cell Therapies
  • 3.4 Bone Marrow Transplants
    • 3.4.1 Graft-versus-Host Disease and Host-versus-Graft Disease
    • 3.4.2 Bone Marrow Transplants and Medicare Coverage
    • 3.4.3 Private Bone Marrow Transplant Forecast 2011-2021
    • 3.4.4 Peripheral Blood Stem Cell Transplants
    • 3.4.5 Cord Blood Stem Cell Transplants
  • 3.5 Stem Cell Services
    • 3.5.1 Disease Modelling
    • 3.5.2 Toxicity Screening
    • 3.5.3 Stem Cell Services Market Forecast 2011-2021
  • 3.6 Blood Banking
    • 3.6.1 Private vs. Public Blood Banks
    • 3.6.2 Arguments For and Against Cord Blood Banking
    • 3.6.3 Private Cord Blood Banking Market Forecast 2011-2021

4. Companies Driving the Stem Cells Market

  • 4.1 Leading Companies Developing Stem Cell Therapies
    • 4.1.1 Aastrom Biosciences
    • 4.1.2 Advanced Cell Technology
    • 4.1.3 AmStem
    • 4.1.4 Athersys
    • 4.1.5 BioHeart
    • 4.1.6 BrainStorm Cell Therapeutics
    • 4.1.7 Cytori Therapeutics
    • 4.1.8 Gamida Cell
    • 4.1.9 Geron
      • 4.1.9.1 Geron and GE Healthcare
    • 4.1.10 MediStem Laboratories
    • 4.1.11 Mesoblast
    • 4.1.12 Neostem
    • 4.1.13 Neuralstem
    • 4.1.14 Opexa Therapeutics
      • 4.1.14.1 Tovaxin
    • 4.1.15 Osiris Therapeutics
      • 4.1.15.1 Prochymal
      • 4.1.15.2 Chondrogen
    • 4.1.16 Pluristem Therapeutics
    • 4.1.17 Reliance Life Sciences
    • 4.1.18 ReNeuron
    • 4.1.19 StemCells
    • 4.1.20 TCA Cellular Therapy
  • 4.2 Some Companies Offering Stem Cell Services
    • 4.2.1 Axiogenesis
    • 4.2.2 BioTime
      • 4.2.2.1 CellCure Neurosciences
    • 4.2.3 CellCyte Genetics
    • 4.2.4 Cellular Dynamics International
    • 4.2.5 International Stem Cell Corp
    • 4.2.6 MultiCell Technologies
    • 4.2.7 Regenetech
    • 4.2.8 Stem Cell Innovations
    • 4.2.9 Stemgent
    • 4.2.10 Thermo Fisher Scientific/HyClone
    • 4.2.11 ViaCyte
    • 4.2.12 Vitro Biopharma
  • 4.3 Selected Private Cord Blood Banks
    • 4.3.1 Biogenea-Cellgenea
    • 4.3.2 China Cord Blood Corp
    • 4.3.3 Cord Blood America
    • 4.3.4 Cryo-Cell International
    • 4.3.5 Cryo-Save
    • 4.3.6 LifebankUSA
    • 4.3.7 Thermogenesis
    • 4.3.8 ViaCord

5. Issues Affecting the Stem Cell Technologies Market 2011-2021

  • 5.1 SWOT Chart for the Stem Cells Market 2011-2021
  • 5.2 Strengths
    • 5.2.1 Stem Cell Therapies Already Have a Number of Applications
    • 5.2.2 Stem Cells Have Vast Therapeutic Potential
    • 5.2.3 Stem Cells Have Uses Beyond Therapy
    • 5.2.4 Strength in Numbers
    • 5.2.5 Strong Government Support for Stem Cells
  • 5.3 Weaknesses
    • 5.3.1 The Research Field is Fragmented
    • 5.3.2 A Complex Intellectual Property Environment
    • 5.3.3 Research Relies Too Heavily on Government Funding
    • 5.3.4 Difficulties in Scaling Up
    • 5.3.5 Neither Autologous nor Allogeneic Therapies Are Perfect Yet
      • 5.3.5.1 Autologous Therapies
      • 5.3.5.2 Allogeneic Therapies
      • 5.3.5.3 Incompatibility with the Existing Pharmaceutical Model?
  • 5.4 Opportunities
    • 5.4.1 Leading Pharma Companies Investing in Stem Cell Research
    • 5.4.2 The Potential of iPSCs
      • 5.4.2.1 Transdifferentiation
    • 5.4.3 Philanthropy May Prove a Good Source of Funding
    • 5.4.4 Asia Offers Dynamic Opportunities
      • 5.4.4.1 South Korea
      • 5.4.4.2 Israel
    • 5.4.5 The First New Therapies Launched Will Drive Market Growth
  • 5.5 Threats
    • 5.5.1 Some Companies Will Fail
      • 5.5.1.1 Case Study: Garnet BioTherapeutics
    • 5.5.2 Maintaining Public Support is Vital but Difficult
    • 5.5.3 Difficulties with Animal Models
    • 5.5.4 There Remains Uncertainty in the Future Pathway of US Research
    • 5.5.5 Rapid Progress Makes Certain Discoveries Obsolete

6. Therapeutic Applications for Stem Cell Therapies 2011-2021

  • 6.1 Near-Term Indications
    • 6.1.1 Cancer
      • 6.1.1.1 Cancer Stem Cells
    • 6.1.2 Immune Disorders
    • 6.1.3 Eye Diseases
    • 6.1.4 Orthopaedics
    • 6.1.5 Diabetes
  • 6.2 Cardiovascular Diseases
  • 6.3 Central Nervous System (CNS) Diseases
    • 6.3.1 Amyotrophic Lateral Sclerosis (ALS)
    • 6.3.2 Multiple Sclerosis
    • 6.3.2.1 Pelizaeus-Merzbacher Disease (PMD)
    • 6.3.3 Alzheimer' s Disease
    • 6.3.4 Cerebral Palsy
    • 6.3.5 Parkinson' s Disease
    • 6.3.6 Spinal Cord Injury
  • 6.4 Growing Organs

7. Regional Analysis of the Stem Cells Market 2011-2021

  • 7.1 Global Spread of Stem Cell Research
  • 7.2 The United States
    • 7.2.1 US Market Drivers and Restraints, 2011-2021
    • 7.2.2 California Institute of Regenerative Medicine (CIRM)
  • 7.3 Japan
    • 7.3.1 Commercial Aspects of Stem Cells in Japan
  • 7.4 Europe
    • 7.4.1 The UK
    • 7.4.2 Spain
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 Italy
  • 7.5 China
  • 7.6 India

8. Research Interview

  • 8.1 Yael Margolin, President and CEO, Gamida Cell
    • 8.1.1 Challenges in Developing Stem Cell Therapies
    • 8.1.2 Israel' s Strength in Stem Cell Research
    • 8.1.3 Public Perception of Stem Cell Therapies
    • 8.1.4 Therapeutic Targets and Gamida Cell' s Stem Cell Therapies
    • 8.1.5 Umbilical Cord Blood Stem Cells

9. Conclusions

  • 9.1The Stem Cells Market is Currently Small
  • 9.2 Market Growth Will be Dependent on Stem Cell Therapies
  • 9.3 Induced Pluripotent Stem Cells Represent a Strong Market Opportunity
  • 9.4 Stem Cell Therapies Will be Used in Many Disease Areas
  • 9.5 Concluding Remarks

List of Tables

  • Table 1.1 Currency Exchange Rates, 2009-2010
  • Table 2.1 Potency and Source of Stem Cells
  • Table 2.2 Germ Layers and Their Associated Types of Cells and Organs
  • Table 3.1 Global Stem Cell Market, 2010
  • Table 3.2 Global Stem Cells Market: Forecast, 2010-2021
  • Table 3.3 Global Stem Cells Market: Drivers and Restraints, 2011-2021
  • Table 3.4 Selected Uses for Stem Cells Therapies, 2011
  • Table 3.5 Stem Cell Therapies Market: Drivers and Restraints, 2011-2021
  • Table 3.6 Osteocel Plus Sales Forecast, 2010-2021
  • Table 3.7 Companies Not Considered Part of the Stem Cell Market in this Report
  • Table 3.8 Sources of Stem Cells for Bone Marrow Transplants
  • Table 3.9 Medicare Coverage for Bone Marrow Transplants, 2011
  • Table 3.10 Bone Marrow Transplants Market: Drivers and Restraints, 2011-2021
  • Table 3.11 Stem Cell Services Market: Drivers and Restraints, 2011-2021
  • Table 3.12 Costs of Various Private Cord Blood Banks Worldwide, 2011
  • Table 3.13 Cord Blood Banking Market: Drivers and Restraints, 2011-2021
  • Table 4.1 Selected Stem Cell Therapy Companies and Their Leading Products, 2011
  • Table 4.2 Histostem' s Leading Clinical Investigations, 2011
  • Table 4.3 MultiStem Pipeline, 2011
  • Table 4.4 Gamida Cell' s Stem Cell Therapy Pipeline, 2011
  • Table 4.5 Geron' s Stem Cell Therapy Pipeline, 2011
  • Table 4.6 Clinical Progress of GRN-1632, 2011
  • Table 4.7 Osiris Therapeutics Stem Cell Pipeline, December 2010
  • Table 4.8 TCA Cellular Therapy Clinical Progress, 2011
  • Table 4.9 Selected Stem Cell Services Companies, 2011
  • Table 4.10 Selected Private Cord Blood Banks, 2011
  • Table 4.11 China Cord Blood Corp Revenue and Subscribers, 2009-2010
  • Table 4.12 Cryo-Cell International Revenue, 2009-2010
  • Table 4.13 Cryo-Save Revenue and Operating Profit, 2009-2010
  • Table 4.14 Cryo-Save Revenue by Region, 2010
  • Table 5.1 SWOT Analysis of the Market, 2011-2021
  • Table 5.2 NIH Human Stem Cell Research Funding, 2002-2010
  • Table 6.1 Selected Examples of Stem Cell Research, 2010-2011
  • Table 6.2 Stem Cell Clinical Trials by Indication, 2011
  • Table 6.3 Neurodegenerative Diseases: Stem Cell Clinical Trials by Indication, 2011
  • Table 7.1 Stem Cell Clinical Trials by Country, 2011
  • Table 7.2 NIH Stem Cell Research Funding, 2002-2010
  • Table 7.3 CIRM Funding by Disease, 2004-2011
  • Table 7.4 Indian Stem Cell Clinical Trials Conducted, 2011
  • Table 9.1 Stem Cells Market Value and Market Shares, 2010, 2016 and 2021

List of Figures

  • Figure 2.1 The Early History of Stem Cell Discovery and Development
  • Figure 3.1 Global Stem Cell Market, 2010
  • Figure 3.2 Global Stem Cells Market Forecast, 2010-2021
  • Figure 3.3 Stem Cell Therapies Market Forecast, 2010-2021
  • Figure 3.4 Osteocel Plus Sales Forecast, 2010-2021
  • Figure 3.5 Private Bone Marrow Transplant Market Forecast, 2011-2021
  • Figure 3.6 Stem Cell Services Market Forecast, 2010-2021
  • Figure 3.7 Twenty Year Storage Costs at Various Private Cord Blood Banks Worldwide, 2011
  • Figure 3.8 Cord Blood Banking Market Forecast, 2010-2021
  • Figure 4.1 MultiStem Key Events, 2006-2011
  • Figure 4.2 China Cord Blood Corp Revenue and Subscribers, 2009-2010
  • Figure 4.3 Cryo-Cell International Revenue, 2009-2010
  • Figure 4.4 Cryo-Save Revenue and Operating Profit, 2009-2010
  • Figure 4.5 Cryo-Save Revenue by Region, 2010
  • Figure 5.1 NIH Human Stem Cell Research Funding, 2002-2010
  • Figure 5.2 Pfizer' s Stem Cell Collaborations, 2008-2011
  • Figure 6.1 Stem Cell Clinical Trials for Cancer by Phase, 2011
  • Figure 6.2 Neurodegenerative Diseases: Stem Cell Clinical Trials by Indication, 2011
  • Figure 6.3 Five Stages of Parkinson' s Disease
  • Figure 7.1 Stem Cell Clinical Trials by Country, 2011
  • Figure 7.2 NIH Stem Cell Research Funding, 2002-2010
  • Figure 7.3 Key Events in the US Federal Funding of hESC Research Lawsuit, 2009-2010
  • Figure 7.4 CIRM Funding by Disease, 2004-2011
  • Figure 7.5 Example of the UK Stem Cell Therapy Regulatory Pathway, 2011
  • Figure 9.1 Stem Cells Market by Sector, 2016
  • Figure 9.2 Stem Cells Market by Sector, 2021

Companies Listed

  • Aastrom Biosciences
  • Advanced Cell Technology
  • Agence Nationale de la Recherche [France]
  • Agennix
  • Aldagen
  • Alliance for Regenerative Medicine
  • AlloSource
  • AlphaTec Spine
  • American Heart Association
  • Amgen
  • Amorcyte
  • AmStem
  • AmStem International
  • Angioblast Systems
  • Angiotech
  • Anterogen
  • AstraZeneca
  • Athersys
  • Axiogenesis
  • AXM Pharma
  • Axordia
  • Beike Biotechnology
  • Biogenea-Cellgenea
  • Bioheart
  • BioMimetic Therapeutics
  • BioTime
  • Boston Biomedical
  • BrainStorm Cell Therapeutics
  • California Institute of Regenerative Medicine (CIRM)
  • Care Quality Commission
  • Catalan Institute for Research and Advanced Studies
  • Celgene
  • Cell Cure Neurosciences
  • Cellartis
  • CellCyte Genetics
  • Cellectis
  • Cellerix
  • Cellular Dynamics International
  • CEL-SCI
  • Cephalon
  • Cha General Hospital [South Korea]
  • China Cord Blood Corp
  • Cleveland Clinic
  • Columbia University
  • CorCell Companies
  • Cord Blood America
  • CORD:USE
  • Cryo-Cell International
  • Cryo-Cell Mexico
  • Cryo-Save
  • Cytori Therapeutics
  • Denali Ventures
  • Department for Health and Human Services [US]
  • Department of Biotechnology [India]
  • Department of Defense [US]
  • Department of Health [UK]
  • Drugs Controller of India
  • Duke University Medical Center
  • Ebryome Sciences (now ReCyte Therapeutics)
  • EMA Committee for Orphan Medicinal Products
  • Emerging Healthcare Solutions
  • EpiStem
  • ES Cell International
  • European Court of Justice
  • European Medicines Agency (EMA)
  • EyeCyte
  • Fate Therapeutics
  • FDA Center for Biologics Evaluation and Research [US]
  • Food and Drug Administration (FDA) [US]
  • French National Assembly
  • Gamida Cell
  • Garnet BioTherapeutics
  • GE Healthcare
  • Gene Therapy Advisory Committee [UK]
  • General BioTechnology
  • Genzyme
  • Georgetown University Medical Center
  • Geron
  • GSK
  • Hadassah Hospital [Israel]
  • Harvard Stem Cell Institute
  • HemoGenix
  • Histostem
  • Home Office [UK]
  • Human Fertilisation and Embryology Authority (HFEA) [UK]
  • Human Tissue Authority (HTA) [UK]
  • HyClone
  • Intercytex
  • International Consortium of Stem Cell Networks
  • International Society for Stem Cell Research (ISSCR)
  • International Stem Cell Corp
  • Invitrogen
  • iPS Academia Japan
  • Israel Stem Cell Society
  • Keele University
  • Korea Stem Cell Bank
  • Life R.F.
  • LifebankUSA
  • LifeCell International
  • Lifeline Cell Technology
  • Lonza
  • Maxim Biotech
  • Medical College of Georgia
  • Medical Research Council [UK]
  • Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
  • Medipost Co
  • MediStem Laboratories
  • Medtronic
  • Mesoblast
  • Miltenyi Biotec
  • Ministero della Salute [Italy]
  • Ministry of Education, Culture, Sports, Science and Technology [Japan]
  • Ministry of Health [China]
  • Ministry of Science and Technology [China]
  • Minneapolis Heart Institute
  • MultiCell Technologies
  • Musculoskeletal Transplant Foundation [US]
  • Mytogen
  • NacalaiTesque
  • NASA
  • National Center for Cell Science [India]
  • National Health Service (NHS) [UK]
  • National Heart, Lung and Blood Institute [US]
  • National Institutes of Health (NIH) [US]
  • National Marrow Donor Program [US]
  • National Multiple Sclerosis Society [US]
  • NeoStem
  • Neuralstem
  • New York Stem Cell Foundation
  • Nippon Zoki Pharmaceutical
  • Northwestern University
  • Novartis
  • Novo Nordisk
  • NuVasive
  • Odontis
  • Oklahoma State House
  • Oncocyte
  • OncoMed Pharmaceuticals
  • Opexa Therapeutics
  • Organogenesis
  • OrthoCyte
  • Orthofix
  • Osiris Therapeutics
  • Osteotech
  • Oxford University
  • Parkinson' s UK
  • PerkinElmer
  • Pfizer
  • Pfizer Regenerative Medicine
  • Pluristem Therapeutics
  • Progenitor Cell Therapy
  • ReachBio
  • Regenerative Sciences
  • RegeneRx
  • Regenetech
  • Reinnervate
  • Reliance Life Sciences
  • ReNeuron
  • Robert Jones and Agnes Hunt Orthopaedic Hospital
  • Roche
  • RTI Biologics
  • Rutgers University
  • Saneron CCEL Therapeutics
  • sanofi-aventis
  • Sejtbank
  • Seoul National University
  • Spanish Stem Cell Bank
  • Stanford University
  • Stellacure
  • Stem Cell Innovations
  • Stem Cell Therapeutics
  • StemCells
  • Stemgent
  • Stempeutics
  • Stempeutics Research Malaysia
  • SUNY Upstate Medical University
  • Suzhou Neuralstem Biopharmaceutical Company
  • TCA Cellular Therapy
  • Teva
  • Thermo Fisher Scientific
  • Thermogenesis
  • TiGenix
  • Tissue Bank Cryo Center Bulgaria
  • TotipotentSC
  • UK Stem Cell Bank
  • University College London (UCL)
  • University of California
  • University of Edinburgh
  • University of Helsinki
  • University of Kyoto
  • University of Malaya
  • University of Massachusetts
  • University of Michigan
  • University of Modena Centre for Regenerative Health
  • University of Pittsburgh
  • University of Tubingen
  • University of Wisconsin
  • US Army Institute of Surgical Research
  • US Supreme Court
  • Vaxon Biotech
  • Veritas
  • ViaCell
  • ViaCord
  • ViaCyte (formerly Novocell)
  • Vitro Biopharma
  • Voss Laboratories
  • Wake Forest University
  • Walter and Eliza Institute of Medical Research [Australia]
  • Weihei Municipal Price Bureau [China]
  • Wisconsin Alumni Research Foundation (WARF)
  • Xcell Center
  • Zhejiang Lukou Biotechnology Co
Back to Top